Skip to main content

Posts

Showing posts with the label guidance

Palantir Tops $1 Billion in Revenue for the First Time, Boosts Guidance: A Landmark AI-Driven Milestone

Palantir Tops $1 Billion in Revenue for the First Time, Boosts Guidance: A Landmark AI-Driven Milestone What is Palantir's $1 Billion Revenue Milestone? Palantir Technologies has achieved a significant financial milestone, reporting quarterly revenue exceeding $1 billion for the first time in company history. This landmark achievement represents a major turning point for the data analytics company, which has steadily grown since its founding to become a key player in the artificial intelligence software space. The AI software provider's revenues grew an impressive 48% during the second quarter of 2025, directly attributed to the ongoing artificial intelligence boom that has accelerated enterprise adoption of Palantir's platforms. This revenue surge not only demonstrates Palantir's successful pivot toward AI-driven solutions but also validates the company's strategic focus on government and enterprise clients seeking advanced data analytics capabilities. How Does Pal...

Centene (CNC) Q2 2025: Surprise Loss on Medicaid/ACA Costs, Revenue Beats; Stock Rebates on 2026 Outlook

Centene Q2 Loss Highlights Rising Costs Key Takeaways Centene posted a $253M Q2 loss , flipping from a $1.1B profit in 2024 . Medical cost ratio (MCR) surged to 93% , far exceeding Wall Street’s 89.3% forecast . Stock plunged 14.5%  premarket, hitting a decade low and dragging down peers Elevance Health and Molina Healthcare . Loss drivers : Medicaid behavioral/home health costs, ACA risk-adjustment revenue cuts, and high-cost drugs . Corrective action : Premium hikes for 2026 ACA plans in "substantial majority" of states . The Earnings Shock Centene bled red. $253 million vanished in Q2. Last year? A crisp $1.1 billion profit . Premium revenue climbed to $42.5 billion, up 18%, but medical costs devoured it . The street expected an $0.86 per share profit. Instead, Centene coughed up a $0.16 loss . Analysts stared at their screens. Julie Utterback at Morningstar called the 93% medical cost ratio "surprisingly high" . All business lines burned. The ACA marketplace? Th...